Longitude Capital
  • ABOUT
  • TEAM
  • PORTFOLIO
  • NEWS
  • CONTACT
  • LP LOGIN
Select Page

Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST

by Seini Moimoi | May 25, 2023 | Portfolio News

89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

by Seini Moimoi | May 23, 2023 | Portfolio News

Quanta Therapeutics Raises Over $50 Million in Series D Financing to Advance its Pipeline of KRAS Inhibitors

by Seini Moimoi | May 22, 2023 | Portfolio News

Endogenex™ Appoints Christopher Sorli as Chief Medical Officer

by Seini Moimoi | May 18, 2023 | Portfolio News

CG Oncology Announces New Phase 2 Data with Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA® (pembrolizumab) in BCG-Unresponsive NMIBC

by Seini Moimoi | May 1, 2023 | Portfolio News

« Older Entries

Media Contact

Maggie Jamison

mjamison@longitudecapital.com

650-854-5700

  • Facebook
  • Twitter
  • Google
  • RSS
footer-logo

LP Login

© 2023 Longitude Capital. All rights reserved.
  • Privacy Policy
  • Disclaimer